Clinical Trials Browser

Leukemia × obinutuzumab × Other hematologic neoplasm × Clear all

NCT05536349 2026-02-24

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT03836261 2024-12-27

AMPLIFY

Phase 3 Active not recruiting

984 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Phase 1 Completed

119 enrolled 34 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03145480 2023-06-01

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Phase 2 Terminated

3 enrolled 5 charts

Other hematologic neoplasm

Leukemia

NCT03759184 2022-03-22

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Phase 1 Terminated

1 enrolled 13 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia